Clinical Review

Non–Daily-Dosed Rosuvastatin in Statin-Intolerant Veterans

Author and Disclosure Information

The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, also known as statins, are the treatment of choice for hyperlipidemia.(1) Many patients, however, are unable to tolerate statins and subsequently discontinue therapy. The reported incidence of statin intolerance varies widely in the literature. A recent review estimated that 10% to 15% of statin users experience some type of myopathy, which is one of the most common reasons for discontinuation.(2)


 

Recommended Reading

Measuring and Improving the Quality of Oral Anticoagulation for Veterans
Federal Practitioner
Elevated Cardiac Troponins—Not Always an Acute Coronary Syndrome
Federal Practitioner
Sitagliptin's Safety; New Option Approved for Hospital-Acquired Pneumonia; FDA Approves First Nonhormonal Drug for Menopause Symptoms
Federal Practitioner
Safety and Efficacy Comparison of Maximum Dose Simvastatin vs Rosuvastatin
Federal Practitioner
What’s “Real” QOL for AFib Patients?; Stroke Risk and Later Dementia; Encouraging Herpes Zoster Vaccinations
Federal Practitioner
Comparing Treatments for Diabetes and CAD; Putting SSI Prophylaxis to the Test
Federal Practitioner
The Truth About AFib
Federal Practitioner
How Low Is Too Low?
Federal Practitioner
ACE Fit; I Want to Work on My...; Heart360
Federal Practitioner
Bypassing Acute Coronary Syndrome
Federal Practitioner